This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Infusion Rates
CIDP
dosing and
administration
CIDP
infusion rate chart
CIDP
infusion rate calculator
Tab Number 4
Tab Number 5
- In the CIDP study, a loading dose of 2 g/kg of PANZYGA was given followed by 7 maintenance infusions every 3 weeks over a period of 6 months1
- The initial infusion rate should be maintained for 30 minutes, and if tolerated, the infusion rate may be gradually increased every 15 to 30 minutes to a maximum of 12 mg/kg/min (0.12 mL/kg/min) as tolerated1
- PANZYGA should be started at 1 mg/kg/min and continued at the infusion rates stated here, if tolerated1
- The example shown above illustrates a ramp-up schedule for an 80-kg patient using rates of 1, 2, 4, 8, and 12 mg/kg/min
- For patients at risk of renal dysfunction or thromboembolic events, administer PANZYGA at the minimum infusion rate practicable. Do not exceed 3.3 mg/kg/min (0.033 mL/kg/min). Discontinue if renal function deteriorates1
- Loading Dose: 2 g/kg (20 mL/kg), divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days1
- Maintenance Dose: 1 g/kg or 2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days1
- The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15 to 30 minutes, as tolerated, to the maximum infusion rate of 12 mg/kg/min (0.12 mL/kg/min)1
- infusion ramp-up rate to program into an IV infusion pump
- estimated time to complete the infusion
Adult patient with CIDP
One field from each section below is required.
Adult patient with CIDP
Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.
0.01 mL/kg/min
(1 mg/kg/min)
mL/hr
(if previous is tolerated)
0.02 mL/kg/min
(2 mg/kg/min)
mL/hr
(if previous is tolerated)
0.04 mL/kg/min
(4 mg/kg/min)
mL/hr
(if previous is tolerated)
0.08 mL/kg/min
(8 mg/kg/min)
mL/hr
(if previous is tolerated)
0.12 mL/kg/min
(12 mg/kg/min)
mL/hr
(if the rates above are tolerated by the patient)
Patient 2 years or older with PI
One field from each section below is required.
Patient 2 years or older with PI
Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.
0.01 mL/kg/min
(1 mg/kg/min)
mL/hr
(if previous is tolerated)
0.04 mL/kg/min
(4 mg/kg/min)
mL/hr
(if previous is tolerated)
0.08 mL/kg/min
(8 mg/kg/min)
mL/hr
(if previous is tolerated)
0.14 mL/kg/min
(14 mg/kg/min)
mL/hr
(if the rates above are tolerated by the patient)
Adult patient with cITP
One field from each section below is required.
Enter patient’s body weight
Adult patient with cITP
Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.
0.01 mL/kg/min
(1 mg/kg/min)
mL/hr
(if previous is tolerated)
0.04 mL/kg/min
(4 mg/kg/min)
mL/hr
(if previous is tolerated)
0.08 mL/kg/min
(8 mg/kg/min)
mL/hr
(if the rates above are tolerated by the patient)
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
PP-PAN-USA-0828
PP-PAN-USA-0594
- Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
AND USAGE